Availability of oral antivirals against SARS-CoV-2 infection and the requirement for an ethical prescribing approach

The first two oral antivirals, molnupiravir and nirmatrelvir–ritonavir, are now becoming available in many countries. These medicines will be indicated to treat mild-to-moderate COVID-19 in non-hospitalised patients who are at high risk of progressing to severe COVID-19. These antivirals should be p...

Descripción completa

Detalles Bibliográficos
Autores principales: Dal-Ré, Rafael, Becker, Sören L, Bottieau, Emmanuel, Holm, Søren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Personal View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963769/
https://www.ncbi.nlm.nih.gov/pubmed/35364019
http://dx.doi.org/10.1016/S1473-3099(22)00119-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963769/
https://www.ncbi.nlm.nih.gov/pubmed/35364019
http://dx.doi.org/10.1016/S1473-3099(22)00119-0

Ejemplares similares